Related Experiment Video
Updated: Jun 5, 2026
A Melanoma Patient-Derived Xenograft Model
Published on: May 20, 2019
Melanoma-patient-derived xenograft multi-omics resource melPDomiX maps gain- and loss-of-function alterations
Konstantinos Tsingas1, Monzy Thomas2, McKenna Reale2
1Molecular and Cellular Oncogenesis Program, Melanoma Research Center, The Wistar Institute, Philadelphia, Philadelphia, PA 19104, USA; University of Pennsylvania, Philadelphia, PA 19104, USA.
Abstract:
Melanoma is a common and aggressive cancer, with rising incidence in most developed countries. Major discoveries in melanoma biology have been rapidly translated, allowing cures for patients in late-stage disease. Despite these advances, many tumors remain refractory, in part due to an incomplete understanding of the genes and pathways gained or lost during melanoma tumorigenesis. To address this gap and provide a broadly useful resource for the scientific community, we established melPDomiX, a multi-omics cohort of melanoma-patient-derived xenografts. By linking mutations with transcriptomic and proteomic features, melPDomiX enables systematic characterization of gain- and loss-of-function alterations in treatment-refractory melanoma. Using multi-omics integration and structural-context representation, we demonstrate how this resource distinguishes gain- from loss-of-function variants and uncovers new candidate melanoma drivers and therapeutic targets. Together, melPDomiX provides a comprehensive, deeply profiled set of tumor models that supports mechanistic discovery and facilitates the development of improved treatments for this devastating heterogeneous malignancy.
Insights
Researchers created melPDomiX, a multi-omics resource of melanoma patient-derived xenografts. This helps understand gene changes in refractory melanoma, identifying new drivers and therapeutic targets for improved cancer treatments.
Area of Science:
- Oncology
- Genomics
- Proteomics
Background:
- Melanoma is an aggressive cancer with increasing incidence.
- Current treatments are ineffective for some patients due to incomplete understanding of melanoma tumorigenesis.
- There is a need for comprehensive resources to study gene and pathway alterations in refractory melanoma.
Purpose of the Study:
- To establish melPDomiX, a multi-omics cohort of melanoma patient-derived xenografts.
- To systematically characterize gain- and loss-of-function alterations in treatment-refractory melanoma.
- To identify novel melanoma drivers and therapeutic targets.
Main Methods:
- Established a multi-omics cohort of melanoma patient-derived xenografts (melPDomiX).
- Linked mutations with transcriptomic and proteomic features.
- Utilized multi-omics integration and structural-context representation to distinguish variant functions.
Main Results:
- melPDomiX enables systematic characterization of genetic alterations in refractory melanoma.
- The resource successfully distinguishes gain- from loss-of-function variants.
- New candidate melanoma drivers and therapeutic targets were uncovered.
Conclusions:
- melPDomiX is a valuable resource for mechanistic discovery in melanoma.
- This multi-omics approach facilitates the development of improved treatments for heterogeneous melanoma.
- Understanding gene and pathway alterations is crucial for overcoming treatment resistance.
